M
Maria Altamura
Researcher at University of Barcelona
Publications - 86
Citations - 961
Maria Altamura is an academic researcher from University of Barcelona. The author has contributed to research in topics: Receptor & Tachykinin receptor. The author has an hindex of 17, co-authored 86 publications receiving 915 citations.
Papers
More filters
Journal ArticleDOI
Tachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human.
TL;DR: The results indicate that, even when there is a significant redundance in the effects of TKs and in the role of their receptors, the selective blockade of tachykinin NK2 receptors can have functional consequences on human intestinal motility and perception, but this can occur without the disruption of the physiological functions.
Journal ArticleDOI
Tachykinin receptors antagonists: from research to clinic.
Laura Quartara,Maria Altamura +1 more
TL;DR: This chapter describes how, starting from different approaches and through extensive medicinal chemistry studies, several discovery compounds were optimized and reached the development stage and the first tachykinin receptor antagonist to reach the market in 2003 for chemotherapy-induced emesis has been aprepitant.
Journal ArticleDOI
Tachykinin receptor antagonists in clinical trials
TL;DR: The field is still well active, as currently proof-of-concept studies for indications initially missed (i.e., depression) are ongoing and new targets are under investigation.
Journal ArticleDOI
Mass spectrometry and combinatorial chemistry: a short outline.
TL;DR: Some examples from the laboratory deal with the analysis of pooled oligomeric libraries containing n x 324 compounds, using both on-line high-performance liquid chromatography/MS with an ion trap mass spectrometer, and direct infusion into a triple quadrupole instrument.
Journal ArticleDOI
Nonpeptide antagonists for kinin receptors.
TL;DR: Several quinoline and imidazo[1,2-a]pyridine derivatives have been shown by Fujisawa to possess high affinity and selectivity for kinin B2 receptors, whileFR 173657 displayed excellent in vitro and in vivo antagonistic activity, while FR 190997 emerged as the first nonpeptide agonist for B2 receptor.